American Century Companies Inc. lowered its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 12.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,435,840 shares of the medical research company’s stock after selling 353,881 shares during the quarter. American Century Companies Inc.’s holdings in Edwards Lifesciences were worth $354,585,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in Edwards Lifesciences by 1.6% in the 1st quarter. BlackRock Inc. now owns 15,653,522 shares of the medical research company’s stock worth $2,183,978,000 after acquiring an additional 242,785 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Edwards Lifesciences by 5.3% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,147,510 shares of the medical research company’s stock worth $312,614,000 after acquiring an additional 107,676 shares during the period. Royal Bank of Canada raised its holdings in Edwards Lifesciences by 9.1% in the 1st quarter. Royal Bank of Canada now owns 1,550,377 shares of the medical research company’s stock worth $216,309,000 after acquiring an additional 129,036 shares during the period. CIBC Private Wealth Group LLC raised its holdings in Edwards Lifesciences by 7.2% in the 2nd quarter. CIBC Private Wealth Group LLC now owns 995,781 shares of the medical research company’s stock worth $144,956,000 after acquiring an additional 66,544 shares during the period. Finally, Montag & Caldwell LLC raised its holdings in Edwards Lifesciences by 4.1% in the 1st quarter. Montag & Caldwell LLC now owns 934,768 shares of the medical research company’s stock worth $130,419,000 after acquiring an additional 36,873 shares during the period. Institutional investors and hedge funds own 81.53% of the company’s stock.

NYSE EW opened at $139.77 on Friday. The company has a current ratio of 1.86, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $28.91 billion, a price-to-earnings ratio of 36.78, a P/E/G ratio of 2.01 and a beta of 0.60. Edwards Lifesciences Corp has a 52-week low of $100.20 and a 52-week high of $156.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. The company had revenue of $972.00 million for the quarter, compared to analyst estimates of $968.32 million. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the business posted $1.08 EPS. research analysts forecast that Edwards Lifesciences Corp will post 4.66 EPS for the current fiscal year.

In other news, VP Huimin Wang sold 3,800 shares of Edwards Lifesciences stock in a transaction dated Tuesday, June 5th. The shares were sold at an average price of $142.84, for a total transaction of $542,792.00. Following the sale, the vice president now directly owns 88,388 shares in the company, valued at approximately $12,625,341.92. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 9,815 shares of Edwards Lifesciences stock in a transaction dated Thursday, May 24th. The shares were sold at an average price of $139.39, for a total transaction of $1,368,112.85. Following the sale, the vice president now owns 20,012 shares in the company, valued at $2,789,472.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 160,615 shares of company stock worth $23,053,493. 1.84% of the stock is owned by company insiders.

Several research analysts recently commented on EW shares. Jefferies Financial Group reiterated a “buy” rating and issued a $168.00 target price on shares of Edwards Lifesciences in a report on Friday, July 27th. Royal Bank of Canada lifted their target price on shares of Edwards Lifesciences to $145.00 and gave the stock an “outperform” rating in a report on Wednesday, May 23rd. ValuEngine downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. Raymond James started coverage on shares of Edwards Lifesciences in a report on Thursday, May 31st. They issued an “outperform” rating and a $152.00 target price on the stock. Finally, Northland Securities downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $152.45.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Story: Asset Allocation and Your Retirement

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.